Everolimus Ring-Opening Impurity
|
|
|
- CAS-Nr.
- 1708118-13-1
- Englisch Name:
- Everolimus Ring-Opening Impurity
- Synonyma:
- Everolimus Impurity 33;Everolimus impurity 42;Everolimus Impurity 012-99;Everolimus Open-Ring Impurity;Everolimus Impurity 2（012-99）;Everolimus Impurity 3 (012-99);Everolimus Open-Ring Aldehyde Impurity;EverolimusRetroaldolDegradationProduct;(S)-(2R,3S,6R,E)-1-((1S,3R,4R)-4-(2-hydroxyethoxy);Everolimus Ring-Opening Impurity (Mixture of Isomers)
- CBNumber:
- CB02737607
- Summenformel:
- C53H83NO14
- Molgewicht:
- 958.23
- MOL-Datei:
- 1708118-13-1.mol
|
Everolimus Ring-Opening Impurity Eigenschaften
- Schmelzpunkt:
- 45-50°C
- Siedepunkt:
- 954.8±75.0 °C(predicted)
- Dichte
- 1.15±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)
- storage temp.
- Amber Vial, -86°C Freezer, Under inert atmosphere
- L?slichkeit
- Chloroform (Slightly), Methanol (Slightly)
- Aggregatzustand
- Solid
- pka
- 10.56±0.60(predicted)
- Farbe
- White to Off-White
- Stabilit?t:
- Light and temperature Sensitive
Sicherheit
Everolimus Ring-Opening Impurity Chemische Eigenschaften,Einsatz,Produktion Methoden
Verwenden
Everolimus Retroaldol Degradation Product is an impurity of Everolimus (E945400). Everolimus is a derivative of Rapamycin. Everolimus inhibits cytokine-mediated lymphocyte proliferation. Everolimus Impurity D
Everolimus Ring-Opening Impurity Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Everolimus Ring-Opening Impurity Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 36)Lieferanten
- EverolimusRetroaldolDegradationProduct
- (S)-(2R,3S,6R,E)-1-((1S,3R,4R)-4-(2-hydroxyethoxy)
- Everolimus Impurity 012-99
- Everolimus Open-Ring Impurity
- Everolimus Open-Ring Aldehyde Impurity
- Everolimus Impurity 33
- (2R,3S,6R,E)-1-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-2,6,8-trimethyl-5,9-dioxonon-7-en-3-yl (S)-1-(2-((2R,3R,6S)-6-((2S,3E,5E,7E,9S,11R)-2,13-dimethoxy-3,9,11-trimethyl-12-oxotrideca-3,5,7-trien-1-yl)-2-hydroxy-3-methyltetrahydro-2H-pyran-2-yl)-2-oxoacetyl)piperidine-2-carboxylate
- (S)-(2R,3S,6R,E)-1-((1S,3R,4R)-4-(2-Hydroxyethoxy)-3-methoxycyclohexyl)-2,6,8-trimethyl-5,9-dioxonon-7-en-3-yl 1-(2-((2R,3R,6S)-6-((2S,3E,5E,7E,9S,11R)-2,13-dimethoxy-3,9,11-trimethyl-12-oxotrideca-3,5,7-trien-1-yl)-2-hydroxy-3-methyltetrahydro-2H-pyran-2-yl)-2-oxoacetyl)piperidine-2-carboxylate
- Everolimus Impurity 2（012-99）
- 2-Piperidinecarboxylic acid, 1-[2-[(2R,3R,6S)-6-[(2S,3E,5E,7E,9S,11R)-2,13-dimethoxy-3,9,11-trimethyl-12-oxo-3,5,7-tridecatrien-1-yl]tetrahydro-2-hydroxy-3-methyl-2H-pyran-2-yl]-2-oxoacetyl]-, (1S,4R,5E)-1-[(1R)-2-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-1-methylethyl]-4,6-dimethyl-3,7-d...
- Everolimus Ring-Opening Impurity (Mixture of Isomers)
- EVEROLIMUS RETROALDOL DEGRADATION (ISOMER 1 + ISOMER 2)
- 2-Piperidinecarboxylic acid, 1-[2-[(2R,3R,6S)-6-[(2S,3E,5E,7E,9S,11R)-2,13-dimethoxy-3,9,11-trimethyl-12-oxo-3,5,7-tridecatrien-1-yl]tetrahydro-2-hydroxy-3-methyl-2H-pyran-2-yl]-2-oxoacetyl]-, (1S,4R,5E)-1-[(1R)-2-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-1-methylethyl]-4,6-dimethyl-3,7-dioxo-5-hepten-1-yl ester, (2S)-
- Everolimus impurity 42
- Everolimus Impurity 3 (012-99)
- 1708118-13-1
